02 May, 2022
BOSTON , May 02, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that management will present and be available for one-on-one meetings at the following upcoming
29 Apr, 2022
BOSTON , April 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter ended March 31, 2022 .
17 Feb, 2022
Continued pipeline progress with three potentially first-in-class product candidates Strong cash position with cash runway into 2H 2024 BOSTON , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for
07 Feb, 2022
BOSTON , Feb. 07, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that management will be participating virtually at two upcoming conferences.